… In conclusion, this retrospective cohort study found that nirmatrelvir/ritonavir was not
associated with a statistically significant reduction in long COVID symptoms overall, but was …

… This study confirms the effectiveness of nirmatrelvir plus ritonavir in preventing hospitalization
and death among vaccinated and unvaccinated persons aged 50 years or older with …

… Therefore, aim of this study was to evaluate in a real life setting the overall tolerability and
safety of molnupiravir and nirmatrelvir/ritonavir by retrospectively assessing the proportions …

… Our study of real-world use of nirmatrelvir–ritonavir in outpatients at high risk extends previous
data by showing strong evidence of nirmatrelvir–ritonavir benefit during the omicron BA.4 …

… cohort study, we aimed to evaluate the real-world effectiveness of Azvudine versus
nirmatrelvir–ritonavir … To our knowledge, this is the first real-world study exploring the inpatient use …

… cohort study of non-hospitalized cases with SARS-CoV-2 infection to compare outcomes
among those who received or did not receive nirmatrelvir-ritonavir … of nirmatrelvir-ritonavir in …

… In this retrospective cohort study, we sought to compare the effectiveness of sotrovimab,
molnupiravir, and nirmatrelvir-ritonavir in preventing hospital admission and death in higher-risk …

… In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12 years or older
with … We aimed to establish the effectiveness of nirmatrelvir–ritonavir in preventing hospital …

… azvudine and nirmatrelvir-ritonavir is urgently needed. In this retrospective cohort study, we
… efficacy and safety of azvudine and nirmatrelvir-ritonavir in hospitalized adult patients with …

… study aimed to examine the effect of nirmatrelvir–ritonavir on … In the nirmatrelvir–ritonavir
group compared with the control … This study showed extended benefits of nirmatrelvir–ritonavir …